Qualigen Therapeutics (QLGN) regained compliance with Nasdaq's minimum bid price and stockholders' equity requirements.
Nasdaq will monitor compliance for a year to ensure long-term compliance with listing requirements, Qualigen said Thursday in a statement.
Shares of the company fell 2.5% in recent Thursday trading.
Price: 4.63, Change: -0.12, Percent Change: -2.48